224 results match your criteria: "Kansas City S.P.; and Virginia Commonwealth University[Affiliation]"
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study.
Neurology
November 2022
From the Department of Neurology (L.S., C.S., N.K., S.E., A.C., S.C., F.I., K.F., Shadi Yaghi), Brown University, Providence, RI; Department of Neurology (E.B.), University of Alabama at Birmingham; Department of Neurology (S.S.O.), University of Colorado School of Medicine, Aurora; Department of Neurology (J.G., J.A.), Washington University, Saint Louis, MO; Departments of Neurology (N.H., M.D.M.), and Psychiatry (N.H.), University of Massachusetts, Worcester; Department of Neurology (A.L.), Weill Cornell Medical Center, New York, NY; Department of Neurology (K.M., J.R.), Montefiore Medical Center, New York, NY; Department of Neurology (R.S., Yee Cheng, A.S.Z., A.H.), Yale University, New Haven, CT; Department of Neurology (Alexis Simpkins, G.L., J.K., D.P.), University of Florida, Gainesville; Department of Neurology (M.R.H., Adrian Scutelnic, R.M., B.S.), Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Neurology (A.R., O.K., D.D.), University of Pennsylvania, Philadelphia; Departments of Neurology (S.A.K., L.A.R.) and Neurosurgery (S.A.K.), Medical University of South Carolina, Charleston; Department of Neurology and Rehabilitation Medicine (E.A.M., Pooja Khatri, Y.A., B.C.), University of Cincinnati; Department of Neurology (D.K., H.L.), Vanderbilt University, Nashville, TN; Department of Neurology (T.N.N., Piers Klein, H.J.A.), Boston University School of Medicine, MA; Department of Neurology (J.A.F., L.K., S.A.), New York University, NY; Department of Neurology (V.M.), University of Utah, Salt Lake City; Department of Neurology (T.W., D.W.), Christchurch Hospital, New Zealand; Department of Neurology (A.N., D.A.), Hartford Hospital, CT; Department of Neurology (A.Q., J.M.), University of Kansas, Kansas City; Department of Neurology (M.K., Yao Cheng), Spectrum Health, Michigan State University, Grand Rapids, MI; Department of Neurology (B.M.G., M.W., D.R.), Duke University, Durham, NC; Department of Medicine and Surgery (M.C.V.), University of Perugia, Italy, University of Perugia, Italy; Neurology-Stroke Unit (Maurizio Paciaroni), IRCCS MultiMedica, Milano, Italy; Cooper Neurologic Institute (J.S., S.K., Siyuan Yu), Cooper University, Camden, NJ; Department of Neurology (C.L.G., E.A.), George Washington University, District of Columbia; Department of Neurology (G.M.D.M., T.D.), University Hospital Basel and University of Basel, Switzerland; Department of Interventional and Diagnostic Neuroradiology (A.B., Marios Psychogios), Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland; Department of Neurology (R.A.-D., T.K.-H., S.P.), University of Chicago, IL; and Department of Neurology (T.H., D.L.), University of California at Los Angeles.
Background And Objective: Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There are limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors.
View Article and Find Full Text PDFA multicenter prospective cohort study of endoscopic urethral realignment versus suprapubic cystostomy after complete pelvic fracture urethral injury.
J Trauma Acute Care Surg
February 2023
From the Division of Urology (B.J.M., S.K.), University of Utah, Salt Lake City, Utah; Department of Urology (J.H.), University of Washington, St. Louis, Michigan; Department of Urology (J.H.), Harborview Medical Center, Seattle, Washington; Department of Urology (J.P.S.), University of Alabama at Birmingham, Birmingham, Alabama; Department of Urology (B.D.F.), University of North Carolina, Chapel Hill, North Carolina; Department of Urology (N.V.J.), Vanderbilt University Medical Center, Nashville, Tennessee; Department of Urology (R.D.d.S.), Denver Health Medical Center, University of Colorado, Denver, Colorado; Department of Urology (J.A.B.), University of Kansas Medical Center, Kansas City, Kansas; Department of Urology (S.G.), University Hospitals, Case Western Reserve University, Cleveland, Ohio; Department of Urology (B.M.), Detroit Medical Center, Detroit, Michigan; Department of Urology (F.N.B.), Beaumont Medical Center, Royal Oak, Michigan; Department of Urology (J.E.), St. Elizabeth's Medical Center (previously Brigham and Women's Medical Center, Boston, Massachusetts), Brighton, Massachusetts; Department of Urology (E.C.O.), University of Texas Dell Medical School, Austin, Texas; Department of Urology (K.J.C.), Emory University School of Medicine (Grady Hospital), Atlanta, Georgia; Department of Urology (B.A.E.), University of Iowa Hospitals and Clinics, Iowa City, Iowa; Department of Urology (M.B.G.), University of Arizona Medical Center, Tucson, Arizona; Department of Urology (P.H.C.), Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania; Santa Clara Valley Medical Center (C.R.H.), Santa Clara, California; Department of Urology (G.P.M.), Washington University School of Medicine, St. Louis, Missouri; Department of Urology (P.R.), University of Pittsburgh Medical Center, Pittsburg, Pennsylvania; Department of Urology (A.S.), University of Tennessee College of Medicine, Chattanooga, Tennessee; Department of Urology (C.B.), Tulane School of Medicine, New Orleans, Louisiana; Division of Urology (A.A.), Rutgers New Jersey Medical School, New Brunswick, New Jersey; Alameda Health System (S.D.B.), Oakland, California; Department of Urology (B.N.B.), University of California, San Francisco, California; Department of Urology (G.M.A.), Icahn School of Medicine at Mount Sinai, New York, New York; Department of Urology (M.M.), Atrium Health, Carolinas Medical Center, Charlotte, North Carolina; Department of Urology (S.P.E.), University of Minnesota, Minneapolis, Minnesota; Department of Urology (I.W.S.), Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota; Einstein Healthcare Network (J.S.), Philadelphia, Pennsylvania; Department of Urology (A.J.V.), Lahey Hospital and Medical Center, Burlington, Massachusetts; Department of Urology (R.A.M.), Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; and Division of Urology (J.B.M.), University of Utah, Salt Lake City, Utah.
Background: Pelvic fracture urethral injury (PFUI) occurs in up to 10% of pelvic fractures. There is mixed evidence supporting early endoscopic urethral realignment (EUR) over suprapubic tube (SPT) placement and delayed urethroplasty. Some studies show decreased urethral obstruction with EUR, while others show few differences.
View Article and Find Full Text PDFDapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Nat Med
September 2022
BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Whether the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and >40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)).
View Article and Find Full Text PDFEfficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Circ Heart Fail
October 2022
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.P., M.V., B.L.C., I.J.K., A.S.D., S.D.S.).
Background: The prevalence of heart failure with mildly reduced or preserved ejection fraction markedly increases with age, with older individuals disproportionately facing excess risk for mortality and hospitalization.
Methods: The DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) randomized patients with New York Heart Association functional class II-IV and left ventricular ejection fraction >40% to either dapagliflozin or placebo for a median follow-up period of 2.3 years.
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Circulation
October 2022
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (J.H.B., P.S.J., J.J.V.M.).
Background: Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).
View Article and Find Full Text PDFDapagliflozin for heart failure according to body mass index: the DELIVER trial.
Eur Heart J
November 2022
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
Aims: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to body mass index (BMI) among patients in the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure trial.
View Article and Find Full Text PDFDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
September 2022
From the Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) - both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke-National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires (J.T.) - both in Argentina; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); General University Hospital, Charles University, Prague, Czech Republic (J.B.); General Clinical Research Center and the Division of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-E.C.); the Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, University of Barcelona, L'Hospitalet de Llobregat, Barcelona (J.C.-C.); George Emil Palade University of Medicine, Pharmacy, Science, and Technology, Târgu Mureş, Romania (D. Dobreanu); the Department of Cardiology, Medical University Lodz, Lodz, Poland (J.D.); University of Utah Medical Center, Salt Lake City (J.C.F.); Centro de Estudios Clínicos de Querétaro, Querétaro, Mexico (M.A.A.-G.); the Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia (W.A.H.); the Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (Y.H.); Clínica Vesalio, San Borja, Peru (J.W.C.H.); the Department of Cardiovascular Diseases, Cardiac Intensive Care, University Hospitals Leuven, Leuven, Belgium (S.P.J.); the Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); Kinshukai Hanwa Daini Senboku Hospital, Osaka, Japan (M.K.); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Institut de Cardiologie de Montréal, Université de Montréal, Montreal (E.O.), and the Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada; the Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil (J.F.K.S.); the Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow (S.N.T.); the Minneapolis Veterans Affairs Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis (O.V.); Cardiovascular Center, Tam Anh Hospital, Tan Tao University, Tan Duc, Vietnam (V.N.P.); and Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (U.W., N.Z., E.B., D.L., M.P., A.M.L.).
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain.
Methods: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy.
Pediatric injury trends and relationships with social vulnerability during the COVID-19 pandemic: A multi-institutional analysis.
J Trauma Acute Care Surg
January 2023
From the Division of Pediatric Surgery, Department of Surgery (K.T.F., M.F., K.V.A., T.T.S.), Medical College of Wisconsin; Children's Wisconsin, Milwaukee, Wisconsin (K.T.F., M.F., K.V.A., T.T.S.); Division of Pediatric Surgery, Department of Surgery (A.T.C., M.P.L., T.A.M.), Indiana University, Indianapolis, Indiana; Norton Children's Hospital, Louisville, KY (M.E.F., D.S.F.); Hiram C. Polk, Jr Department of Surgery (M.E.F., D.S.F.), University of Louisville, Kentucky; Center for Surgical Outcomes Research (P.C.M., K.J.D.), Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine; Department of Pediatric Surgery (P.C.M., K.J.D.), Nationwide Children's Hospital, Columbus, Ohio; Division of Pediatric Surgery (K.E.S., S.G., N.R.), Mott Children's Hospital, Ann Arbor, Michigan; Department of Surgery (J.D.F., S.D.S.P.), Children's Mercy Hospital, Kansas City; Division of Pediatric Surgery (M.S.K.), Washington University School of Medicine, St Louis, Missouri; Division of Pediatric General and Thoracic Surgery (R.A.F.J., M.K.), Cincinnati Children's Hospital Medical Center; Department of Surgery (R.A.F.J., M.K.), University of Cincinnati College of Medicine, Cincinnati, Ohio; and Division of Pediatric Surgery, Department of Surgery (C.M.L.), University of Wisconsin, Madison, Wisconsin.
Background: The impact of the COVID-19 pandemic on pediatric injury, particularly relative to a community's vulnerability, is unknown. The objective of this study was to describe the change in pediatric injury during the first 6 months of the COVID-19 pandemic compared with prior years, focusing on intentional injury relative to the social vulnerability index (SVI).
Methods: All patients younger than 18 years meeting inclusion criteria for the National Trauma Data Bank between January 1, 2016, and September 30, 2020, at nine Level I pediatric trauma centers were included.
Esophageal safety in CLOSE-guided 50 W high-power-short-duration pulmonary vein isolation: The PREHEAT-PVI-registry.
J Cardiovasc Electrophysiol
November 2022
Klinikum Chemnitz-MEDiC, Chemnitz, Germany.
Introduction: Pulmonary vein isolation (PVI) using high-power-short-duration (HPSD) radiofrequency ablation (RF) is emerging as the standard of care for treatment of atrial fibrillation (AF). While procedural short-term to midterm efficacy and efficiency are very promising, this registry aims to investigate esopahgeal safety using an optimized ablation approach.
Methods: In a single-center experience, 388 consecutive standardized first-time AF ablation were performed using a CLOSE-guided-fixed-50 W-circumferential PVI and substrate modification without intraprocedural esophageal temperature measurement.
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Blood Adv
February 2023
Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.
Article Synopsis
- Tisagenlecleucel, a CAR T-cell therapy targeting CD19, has shown remarkable response rates in patients up to age 26 with refractory B-cell acute lymphoblastic leukemia and is FDA approved for this use.
- * A study analyzed data from 185 patients to determine the effects of different CAR T-cell doses on overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS).
- * Results indicated that higher doses of tisagenlecleucel improved survival and remission rates without increasing toxicity, suggesting the potential benefits of targeting higher doses within the approved range for better outcomes.
Fluoroless Versus Conventional Mapping and Ablation of Ventricular Arrhythmias Arising From the Left Ventricular Summit and Interventricular Septum.
Circ Arrhythm Electrophysiol
July 2022
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.R., A.V., I.A., D.B., M.G., E.P., K.F., A.P., J.B., X.Z., M.G., S.P., D.P., V.G., L.D.B.).
Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
N Engl J Med
July 2022
From the Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville (N.B.H.); the Covid-19 Response Team, Centers for Disease Control and Prevention (S.M.O., A.M.P., S.M.G., K.N.P., A.P.C., M.M.P.), the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (S.K.), and the Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta (K.M.T.) - all in Atlanta; the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati (M.A.S.), the Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital, Columbus (K.E.B.), and the Division of Critical Care Medicine, Department of Pediatrics, Akron Children's Hospital, Akron (R.A.N.) - all in Ohio; the Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital (M.M.N., A.G.R.), and the Departments of Anaesthesia and Pediatrics, Harvard Medical School (A.G.R.) - both in Boston; the Division of Infectious Diseases, Children's Hospital Los Angeles, and the Departments of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Los Angeles, Los Angeles (P.S.P.), the Division of Pediatric Hospital Medicine, UC San Diego-Rady Children's Hospital, San Diego (M.A.C.), the Department of Pediatrics, Divisions of Critical Care Medicine and Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, San Francisco (M.S.Z.), and the Division of Critical Care Medicine, UCSF Benioff Children's Hospital, Oakland (N.Z.C.) - all in California; the Department of Pediatrics, Baylor College of Medicine, Immunization Project, Texas Children's Hospital, Houston (J.A.B., L.C.S.); the Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia (K.C.); the Department of Pediatrics, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson (C.V.H.); the Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine, and Children's Hospital Colorado, Aurora (A.B.M.); the Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (B.M.C., K.N.M.); the Division of Pediatric Critical Care Medicine, Children's Hospital of Michigan, Central Michigan University, Detroit (S.M.H.), and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mott Children's Hospital and University of Michigan, Ann Arbor (H.R.F.); the Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock (K.I.); the Division of Pediatric Critical Care Medicine (E.H.M.), and the Department of Pediatrics (L.S.), Medical University of South Carolina, Charleston; the Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill (S.P.S., T.C.W.); the Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas Medical Center, Livingston, NJ (S.J.G.); the Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri (J.E.S.); the Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (S.S.B.); the Department of Pediatrics, Division of Critical Care Medicine, University of Texas Southwestern, Children's Medical Center, Dallas (M.M.); the Division of Pediatric Critical Care, University of Minnesota Masonic Children's Hospital, Minneapolis (J.R.H.), and the Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester (E.R.L.) - both in Minnesota; the Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City (H.C.); the Department of Pediatrics, Division of Cardiology, Louisiana State University Health Sciences Center and Children's Hospital of New Orleans, New Orleans (T.T.B.); the Division of Pediatric Critical Care, Department of Pediatrics, Children's Hospital and Medical Center, Omaha, NE (M.L.C.); and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham (M.K.).
Article Synopsis
- Infants under 6 months old are at high risk for severe Covid-19 complications and can't be vaccinated, but maternal vaccination may provide them with protective antibodies.
- A study comparing hospitalized infants with and without Covid-19 found that the maternal vaccination effectiveness against hospitalization was 52% overall, varying significantly between the delta (80%) and omicron (38%) periods.
- Among 537 case infants, a small percentage had vaccinated mothers, and only 21% required intensive care, with two deaths occurring in unvaccinated cases.
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
Circ Heart Fail
June 2022
Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (J.A.E., P.W.A.).
Article Synopsis
- The study evaluated the impact of vericiguat versus placebo on health status in heart failure patients, focusing on the Kansas City Cardiomyopathy Questionnaire (KCCQ) over 32 weeks.
- Results indicated no significant difference in KCCQ score improvements between the vericiguat and placebo groups, although both groups saw a similar median improvement in clinical summary scores after 16 weeks.
- Vericiguat did lower the risk of cardiovascular death or hospitalizations for heart failure consistently across different baseline health statuses, but overall health status as measured by KCCQ remained unchanged compared to placebo.
Artificial intelligence-assisted optical diagnosis for the resect-and-discard strategy in clinical practice: the Artificial intelligence BLI Characterization (ABC) study.
Endoscopy
January 2023
Gastroenterology Unit, Valduce Hospital, Como, Italy.
Background: Optical diagnosis of colonic polyps is poorly reproducible outside of high volume referral centers. The present study aimed to assess whether real-time artificial intelligence (AI)-assisted optical diagnosis is accurate enough to implement the leave-in-situ strategy for diminutive (≤ 5 mm) rectosigmoid polyps (DRSPs).
Methods: Consecutive colonoscopy outpatients with ≥ 1 DRSP were included.
Quantitative CT Characteristics of Cluster Phenotypes in the Severe Asthma Research Program Cohorts.
Radiology
August 2022
From the Division of Pulmonary, Critical Care, and Sleep Medicine, Rush University Medical Center, Chicago, Ill (A.P.T.); Division of Pulmonary and Critical Care Medicine, University of Kansas School of Medicine, Kansas City, KS 66103-2937 (C.H., M.C.); Division of Biostatistics (C.W.G., D.L., K.B.S.), Division of Pulmonary and Critical Care Medicine (J.G.K., M.C.M., M.S.), Washington University School of Medicine, St Louis, Mo; Department of Radiology, University of Iowa, Iowa City, Iowa (J.P.S., J.M.R., J.D.N., E.A.H.); Department of Medicine, University of Arizona, Tucson, Ariz (H.L., E.R.B., D.A.M.); VIDA Diagnostics, Coralville, Iowa (J.S., S.M., S.P.); Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston-Salem, NC (W.C.M.); Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass (E.I., G.R.W., B.D.L.); Department of Radiology (J.K.L.) and Division of Pulmonary, Allergy and Critical Care Medicine (S.E.W.), University of Pittsburgh, Pittsburgh, Pa; Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, Calif (J.V.F.); Department of Radiology (M.L.S., S.B.F.) and Division of Allergy, Pulmonary and Critical Care Medicine (N.N.J.), University of Wisconsin, Madison, Wis; Department of Public Health Sciences, Penn State Eberly College of Science, University Park, Pa (D.T.M.); and Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Tex (A.S.).
Background Clustering key clinical characteristics of participants in the Severe Asthma Research Program (SARP), a large, multicenter prospective observational study of patients with asthma and healthy controls, has led to the identification of novel asthma phenotypes. Purpose To determine whether quantitative CT (qCT) could help distinguish between clinical asthma phenotypes. Materials and Methods A retrospective cross-sectional analysis was conducted with the use of qCT images (maximal bronchodilation at total lung capacity [TLC], or inspiration, and functional residual capacity [FRC], or expiration) from the cluster phenotypes of SARP participants (cluster 1: minimal disease; cluster 2: mild, reversible; cluster 3: obese asthma; cluster 4: severe, reversible; cluster 5: severe, irreversible) enrolled between September 2001 and December 2015.
View Article and Find Full Text PDFTumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST ( NCT02848651 ), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n = 152). The co-primary endpoints were investigator-assessed objective response rate (ORR) per RECIST version 1.
View Article and Find Full Text PDFPrognostic Relationship Between Coronary Artery Calcium Score, Perfusion Defects, and Myocardial Blood Flow Reserve in Patients With Suspected Coronary Artery Disease.
Circ Cardiovasc Imaging
April 2022
Saint Luke's Mid America Heart Institute, Kansas City, MO (K.K.P., P.A.P.-O., F.S.P., B.W.S., A.I.M., R.C.T., K.F.K., P.S.C., J.A.S., T.M.B.).
Background: Coronary artery calcium score (CACS) is an anatomic measure of calcified atherosclerosis. Myocardial perfusion defects and reduced myocardial blood flow reserve (MBFR) are physiological measures of ischemia and coronary circulatory health. We aimed to assess the relative prognostic importance of MBFR, perfusion defects, and CACS in patients with suspected coronary artery disease.
View Article and Find Full Text PDFImpact of the COVID-19 Pandemic on Exercise Habits Among US Primary Care Patients.
J Am Board Fam Med
April 2022
From School of Medicine, University of Kansas Medical Center, Kansas City, KS (NWB); Department of Family Medicine and Community Health, University of Kansas Medical Center, Kansas City, KS (DJP, NTY).
Background: To explore how the COVID-19 pandemic has affected exercise habits, we hypothesized that participants' physical activity would have increased by at least 30 min/wk after the onset of the pandemic.
Methods: We distributed an anonymous survey to ambulatory patients at the Family Medicine Clinic, University of Kansas Medical Center to analyze changes in exercise habits and weight.
Results: Of the 500 adult patients surveyed, 382 were included.
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Circulation
July 2022
University of Groningen, Department of Cardiology, University Medical Center Groningen, The Netherlands (A.A.V.).
Background: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in acute heart failure is not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized).
View Article and Find Full Text PDFBNT162b2 Protection against the Omicron Variant in Children and Adolescents.
N Engl J Med
May 2022
From the Covid-19 Response Team, Centers for Disease Control and Prevention (A.M.P., S.M.O., M.W.T., L.D.Z., A.P.C., M.M.P.), the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (S.K.), and the Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta (K.M.T.) - all in Atlanta; the Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital (M.M.N., A.G.R.), and the Departments of Anaesthesia and Pediatrics, Harvard Medical School (A.G.R.) - both in Boston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville (N.B.H.); the Department of Pediatrics, Baylor College of Medicine, Immunization Project, Texas Children's Hospital, Houston (J.A.B., L.C.S.), and the Department of Pediatrics, Division of Critical Care Medicine, University of Texas Southwestern, Children's Medical Center, Dallas (M.M.); the Division of Infectious Diseases, Children's Hospital Los Angeles and Departments of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Los Angeles (P.S.P.), the Division of Pediatric Hospital Medicine, UC San Diego-Rady Children's Hospital, San Diego (M.A.C.), the Division of Critical Care Medicine, UCSF Benioff Children's Hospital, Oakland (N.Z.C.), and the Department of Pediatrics, Divisions of Critical Care Medicine and Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, San Francisco (M.S.Z.) - all in California; Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock (K.I.); the Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital Columbus (K.E.B.), the Division of Critical Care Medicine, Department of Pediatrics, Akron Children's Hospital, Akron (R.A.N.), and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati (M.A.S.) - all in Ohio; the Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (A.B.M.); the Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill (T.C.W., S.P.S.); the Division of Pediatric Critical Care Medicine (E.H.M.) and the Department of Pediatrics (L.S.), Medical University of South Carolina, Charleston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO (J.E.S.); the Departments of Pediatrics and Microbiology, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson (C.V.H.); the Department of Pediatrics, Division of Cardiology, Louisiana State University Health Sciences Center and Children's Hospital of New Orleans, New Orleans (T.T.B.); the Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester (E.R.L.), and the Division of Pediatric Critical Care, University of Minnesota Masonic Children's Hospital, Minneapolis (J.R.H.) - both in Minnesota; the Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia (K.C.); the Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (S.S.B.); the Division of Pediatric Critical Care Medicine, Children's Hospital of Michigan, Central Michigan University, Detroit (S.M.H.), and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mott Children's Hospital and University of Michigan, Ann Arbor (H.R.F.); the Division of Pediatric Critical Care, Department of Pediatrics, Children's Hospital and Medical Center, Omaha, NE (M.L.C.); the Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas Medical Center, Livingston, NJ (S.J.G.); the Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (B.M. Coates); the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham (M.K.); the Division of Pediatric Infectious Diseases, Department of Pediatrics, UHealth Holtz Children's Hospital, Miami (B.M. Chatani); and the Department of Pediatrics and Banner Children's at Diamond Children's Medical Center, University of Arizona, Tucson (K.V.T.).
Background: Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.
View Article and Find Full Text PDFThe SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Nat Med
March 2022
Institute of Heart Diseases, Medical University, Wroclaw, Poland.
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751 ), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days.
View Article and Find Full Text PDFOculodentodigital Dysplasia: A Cause of Hypomyelinating Leukodystrophy in Adults.
Neurology
April 2022
From the Departments of Neurology and Neurosurgery (M.A.M.-R., S.P., C.L., L.T.T., G.B.), Pediatrics (G.B.), and Human Genetics (G.B.), McGill University; Child Health and Human Development Program (M.A.M.-R., S.P., C.L., L.T.T., G.B.), Research Institute of the McGill University Health Centre, Montréal, Canada; Center for Pediatric Genomic Medicine (I.T.) and Department of Pathology (I.T.), Children's Mercy Hospital; Faculty of Medicine (I.T.), University of Missouri, Kansas City; Department of Neurology (W.K.), Leukodystrophy Center, University of Leipzig Medical Center, Germany; and Department of Specialized Medicine (G.B.), Division of Medical Genetics, Montreal Children's Hospital and McGill University Health Centre, Montréal, Canada.
Relationship Between Myocardial Perfusion Imaging Abnormalities on Positron Emission Tomography and Anginal Symptoms, Functional Status, and Quality of Life.
Circ Cardiovasc Imaging
February 2022
Saint Luke's Mid America Heart Institute, Kansas City, MO (K.K.P., F.S.P., T.M.B., K.F.K., P.A.P.-O., A.I.M., B.W.S., R.C.T., I.M.S., P.G.J., J.A.S.).
Background: Myocardial perfusion imaging (MPI) identifies abnormalities that occur early in the ischemic cascade leading to angina. Our aim was to study the association between ischemic measures on positron emission tomography MPI and patients' health status; their symptoms, function, and quality of life.
Methods: Health status was collected using the Seattle Angina Questionnaire (SAQ-7, 0-100, higher=better) and Rose Dyspnea Score (RDS) on 1515 outpatients with known or suspected coronary artery disease presenting for clinically indicated pharmacological Rb positron emission tomography MPI from July 2018 to July 2019.
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.
Stroke
March 2022
Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).
Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.
Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020.
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
N Engl J Med
February 2022
From the Covid-19 Response Team, Centers for Disease Control and Prevention (S.M.O., A.M.P., L.D.Z., A.P.C., M.M.P.), and the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (S.K.) - both in Atlanta; the Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital (M.M.N., A.G.R.), and the Departments of Anaesthesia and Pediatrics, Harvard Medical School (A.G.R.) - both in Boston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville (N.B.H.); the Department of Pediatrics, Baylor College of Medicine, Immunization Project, Texas Children's Hospital, Houston (J.A.B., L.C.S.), and the Department of Pediatrics, Division of Critical Care Medicine, University of Texas Southwestern, Children's Medical Center Dallas, Dallas (M.M.); the Division of Infectious Diseases, Children's Hospital Los Angeles and Departments of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Los Angeles (P.S.P.), the Division of Pediatric Hospital Medicine, UC San Diego-Rady Children's Hospital, San Diego (M.A.C.), the Division of Critical Care Medicine, UCSF Benioff Children's Hospital Oakland (N.Z.C.), and the Department of Pediatrics, Divisions of Critical Care Medicine and Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, San Francisco (M.S.Z.) - all in California; Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock (K.I.); the Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill (T.C.W., S.P.S.); the Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (A.B.M.); the Division of Pediatric Critical Care Medicine, Medical University of South Carolina, Charleston (E.H.M.); the Department of Pediatrics, Division of Cardiology, Louisiana State University Health Sciences Center and Children's Hospital of New Orleans, New Orleans (T.T.B.); the Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO (J.E.S.); the Division of Critical Care Medicine, Department of Pediatrics, Akron Children's Hospital, Akron (R.A.N.), the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati (M.A.S.), and the Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital Columbus, Columbus (K.E.B.) - all in Ohio; the Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia (K.C.); the Division of Pediatric Critical Care, Department of Pediatrics, Children's Hospital and Medical Center, Omaha, NE (M.L.C.); the Division of Pediatric Critical Care, Department of Pediatrics, Saint Barnabas Medical Center, Livingston, NJ (S.J.G.); the Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester (E.R.L.), and the Division of Pediatric Critical Care, University of Minnesota Masonic Children's Hospital, Minneapolis (J.R.H.) - both in Minnesota; the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham (M.K.), the Division of Pediatric Infectious Diseases, Department of Pediatrics, UHealth/Holtz Children's Hospital, Miami (B.M.C.); the Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (S.S.B.); University of Arizona, Diamond Children's Banner Children's Medical Center, Tucson (M.G.G.); the Department of Pediatrics, Department of Microbiology, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson (C.V.H.); the Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University, Detroit (S.M.H.), and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mott Children's Hospital and University of Michigan, Ann Arbor (H.R.F.); and the Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (K.N.M.).
Background: The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.
View Article and Find Full Text PDF